• Evotec entered a strategic R&D collaboration with Odyssey Therapeutics to discover new small-molecule treatments for autoimmune and inflammatory diseases.
• Odyssey will use Evotec’s AI-enabled discovery platform, screening capabilities, and compound libraries to identify and validate hit series across multiple targets.
• Evotec is eligible for milestone payments tied to delivery of validated hit series for each target; financial terms were not disclosed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evotec SE published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.